

Publikationsliste Dr. Boris-A. Kallmann (Stand 02/2026 - chronologisch)

1. Kallmann, B. A., Burkart, V., Kröncke, K.-D., Kolb-Bachofen, V., & Kolb, H. (1992). Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. *Life Sciences*, 51, 671–678. [https://doi.org/10.1016/0024-3205\(92\)90356-X](https://doi.org/10.1016/0024-3205(92)90356-X)
2. Burkart, V., Imai, Y., Kallmann, B. A., & Kolb, H. (1992). Cyclosporin A protects pancreatic islet cells from nitric oxide-dependent macrophage cytotoxicity. *FEBS Letters*, 313, 56–58. [https://doi.org/10.1016/0014-5793\(92\)80294-7](https://doi.org/10.1016/0014-5793(92)80294-7)
3. Burkart, V., Jalowy, A., Hartmann, B., Kallmann, B. A., Fehsel, K., & Kolb, H. (1992). Nitric oxide as a mediator of autoimmunity in insulin-dependent diabetes. *Immunobiology*, 186, 19–20. (DOI nicht verfügbar)
4. Kallmann, B. A., Kolb, H., Hüther, M., Martin, S., Hellermann, M., & Lampeter, E. F. (1996). Interleukin-10 is a predominant cytokine in atopic dermatitis. *Archives of Dermatology*, 132, 1133–1134. <https://doi.org/10.1001/archderm.132.9.1133>
5. Kallmann, B. A., Hüther, M., Tubes, M., Feldkamp, J., Bertrams, J., Gries, F. A., Lampeter, E. F., & Kolb, H. (1997). Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves' disease. *Diabetes*, 46, 237–243. <https://doi.org/10.2337/diab.46.2.237>
6. Rieckmann, P., Altenhofen, B., Riegel, A., Kallmann, B. A., & Felgenhauer, K. (1998). Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. *Multiple Sclerosis*, 4, 178–182. <https://doi.org/10.1177/135245859800400305>
7. Kallmann, B. A., Lampeter, E. F., Hanifi-Moghaddam, P., Hawa, M., Leslie, R. D. G., & Kolb, H. (1999). Cytokine secretion patterns in twins discordant for type I diabetes. *Diabetologia*, 42, 1080–1085. <https://doi.org/10.1007/s001250051283>
8. Kallmann, B. A., & Malzkorn, R. (1999). Exogenous nitric oxide modulates cytokine production in human leucocytes. *Life Sciences*, 65, 1787–1794. [https://doi.org/10.1016/S0024-3205\(99\)00543-5](https://doi.org/10.1016/S0024-3205(99)00543-5)
9. Rieckmann, P., & Kallmann, B. A. (1999). Immunological parameters and magnetic resonance imaging activity. In A. Siva, J. Kesselring, & A. J. Thompson (Eds.), *Frontiers in Multiple Sclerosis* (pp. 117–125). Martin Dunitz Ltd. (DOI nicht verfügbar)
10. Rieckmann, P., Jung, S., Chan, A., Kallmann, B. A., & Martin, S. (1999). Pathogenesis and therapeutic concepts of organ-specific autoimmune diseases. *Autoimmunity*, 31, 283–288. <https://doi.org/10.3109/08916939909008383>
11. Kallmann, B. A., Hummel, V., Lindenlaub, T., Ruprecht, K., Toyka, K. V., & Rieckmann, P. (2000). Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. *Brain*, 123, 687–697. <https://doi.org/10.1093/brain/123.3.687>
12. Hummel, V., Kallmann, B. A., Füller, T., Wagner, S., Bayas, A., Tonn, J., Benveniste, E., Toyka, K. V., & Rieckmann, P. (2001). The production of MMPs in human cerebral endothelial cells and their role in shedding of adhesion molecules. *Journal of Neuropathology and Experimental Neurology*, 60, 320–327. <https://doi.org/10.1093/jnen/60.3.320>
13. Multiple-Sklerose-Therapie-Konsensus-Gruppe. (2001). Immunmodulatorische Stufentherapie der Multiplen Sklerose. 1. Ergänzung: Dezember 2000. *Nervenarzt*, 72, 150–157. (DOI nicht verfügbar)

14. Multiple-Sklerose-Therapie-Konsensus-Gruppe. (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose. Neue Aspekte und praktische Umsetzung, März 2002. *Nervenarzt*, 73, 556–563. (DOI nicht verfügbar)
15. Kallmann, B. A., Wagner, S., Hummel, V., Bayas, A., Tonn, J. C., & Rieckmann, P. (2002). Characteristic gene expression profile of primary human cerebral endothelial cells. *FASEB Journal Express*. <https://doi.org/10.1096/fj.01-0594fje>
16. Bayas, A., Hummel, V., Kallmann, B. A., Karch, C., Toyka, K. V., & Rieckmann, P. (2002). Human cerebral endothelial cells are a potential source for bioactive BDNF. *Cytokine*, 19(2), 55–58. <https://doi.org/10.1006/cyto.2002.0875>
17. Flachenecker, P., Kümpfel, T., Kallmann, B. A., Gottschalk, M., Grauer, O., Rieckmann, P., Trenkwalder, C., & Toyka, K. V. (2002). Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical parameters. *Multiple Sclerosis*, 8, 523–526. <https://doi.org/10.1191/1352458502ms839oa>
18. Michel, U., Kallmann, B. A., Rieckmann, P., & Isbrandt, D. (2002). UM 9(5)h and UM 9(5)p, a human and a porcine non-coding transcript with preferential expression in the cerebellum. *RNA*, 8, 1538–1547. <https://doi.org/10.1017/S1355838202021538>
19. Kallmann, B. A., & Rieckmann, P. (2002). Chemokines and MS lesion development. *International Journal of Multiple Sclerosis*, 9, 100–107. (DOI nicht verfügbar)
20. Martino, G., Adorini, L., Rieckmann, P., Hillert, J., Kallmann, B. A., Comi, G., & Filippi, M. (2002). Inflammation in multiple sclerosis: The good, the bad, and the complex. *Lancet Neurology*, 1, 499–509. [https://doi.org/10.1016/S1474-4422\(02\)00223-5](https://doi.org/10.1016/S1474-4422(02)00223-5)
21. Kallmann, B. A., & Rieckmann, P. (2003). Was gibt es Neues in der Multiplen Sklerose? *Aktuelle Neurologie*, 30, 421–427. (DOI nicht verfügbar)
22. Kallmann, B. A., Sauer, J., Schließer, M., Warmuth-Metz, M., Flachenecker, P., Becker, G., Rieckmann, P., & Mäurer, M. (2004). Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS) – A two-year follow-up study. *Journal of Neurology*, 251, 30–34. <https://doi.org/10.1007/s00415-004-0430-5>
23. Multiple Sclerosis Therapy Consensus Group. (2004). Escalating immunotherapy of multiple sclerosis. New aspects and practical application. *Journal of Neurology*, 251, 1329–1339. <https://doi.org/10.1007/s00415-004-0512-7>
24. Rieckmann, P., & Kallmann, B. A. (2005). Neue Therapieansätze bei Multipler Sklerose. *Nervenheilkunde*, 4, 294–300. (DOI nicht verfügbar)
25. Kallmann, B. A., Büttner, S., Toyka, K. V., Reiners, K., & Rieckmann, P. (2006). Predictive value of evoked potentials for long-term disease course in multiple sclerosis. *Multiple Sclerosis*, 12, 58–65. <https://doi.org/10.1191/1352458506ms1235oa>
26. Valenza, G., Kallmann, B. A., Berend, A., Mlynski, R., Nöckler, K., Kurzai, O., Abele-Horn, M., & Frosch, M. (2006). Isolation of *Brucella melitensis* from a patient with hearing loss. *European Journal of Clinical Microbiology & Infectious Diseases*. <https://doi.org/10.1007/s10096-006-0084-4>
27. Multiple-Sklerose-Therapie-Konsensus-Gruppe. (2006). Immunmodulatorische Stufentherapie der Multiplen Sklerose – aktuelle Therapieempfehlungen (September 2006). *Nervenarzt*, 77, 1506–1518. (DOI nicht verfügbar)
28. Multiple Sclerosis Therapy Consensus Group. (2008). Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. *Journal of Neurology*, 255, 1449–1463. <https://doi.org/10.1007/s00415-008-0966-3>
29. Arbeitsgruppe Moderne Immuntherapie der MS des Ärztlichen Beirats der Deutschen Multiple Sklerose Gesellschaft. (2009). Therapie der Multiplen Sklerose mit monoklonalen Antikörpern. *Aktuelle Neurologie*. <https://doi.org/10.1055/s-0029-1220429>

30. Bayas, A., Japp, G., Fulda, U., & Kallmann, B. A. (2010). Injektionshilfen in der Basistherapie der Multiplen Sklerose. *Nervenheilkunde*, 1–2, 57–62. (DOI nicht verfügbar)
31. Arbeitsgruppe Moderne Immuntherapie der Multiplen Sklerose. (2011). Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: Aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings. *Aktuelle Neurologie*, 38, 2–11. (DOI nicht verfügbar)
32. Kallmann, B. A. (2011). Multiple Sklerose – Ist eine Neuroprotektion mit aktuellen Therapien möglich? *Neurotransmitter*, 10, 34–41. (DOI nicht verfügbar)
33. Novas, M., Sweetser, M. T., Vigiotta, V., Dawson, K. T., Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., & CONFIRM Study Investigators. (2012). Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *New England Journal of Medicine*, 367(12), 1087–1097. <https://doi.org/10.1056/NEJMoa1105917>
34. Gold, R., Hartung, H. P., Stangel, M., Wiendl, H., & Teilnehmer eines Expertenmeetings. (2012). Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose. *Aktuelle Neurologie*, 39, 342–350. (DOI nicht verfügbar)
35. Stangel, M., Penner, I. K., Kallmann, B. A., Lukas, C., Kieseier, B. C., & Gold, R. (2013). Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose. *Aktuelle Neurologie*, 40, 486–493. (DOI nicht verfügbar)
36. Confavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J. L., Dukovic, D., Truffinet, P., Kappos, L., & TOWER Trial Group. (2014). Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Neurology*, 13(3), 247–256. [https://doi.org/10.1016/S1474-4422\(13\)70308-9](https://doi.org/10.1016/S1474-4422(13)70308-9)
37. Kallmann, B. A., Mäurer, M., Linker, R., & Schwab, S. (2014). Bedeutung regionaler Netzwerke bei der Versorgung von MS-Patienten. *DNP – Der Neurologe und Psychiater*, 15, 64–67. (DOI nicht verfügbar)
38. Stangel, M., Penner, I. K., Kallmann, B. A., Lukas, C., & Kieseier, B. C. (2015). Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: The multiple sclerosis decision model. *Therapeutic Advances in Neurological Disorders*, 8(1), 3–13. <https://doi.org/10.1177/1756285614560733>
39. Miller, D. H., Fox, R. J., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Wheeler-Kingshott, C. A., Tozer, D. J., MacManus, D. G., Yousry, T. A., Goodsell, M., Yang, M., Zhang, R., Vigiotta, V., Dawson, K. T., & CONFIRM study investigators. (2015). Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. *Neurology*. <https://doi.org/10.1212/WNL.0000000000001360>
40. Bayas, A., Ouallet, J. C., Kallmann, B. A., Hupperts, R., Fulda, U., Marhardt, K., & for the SMART Study Group. (2015). Adherence to, and effectiveness of, sc IFN β -1a administered by RebiSmart in patients with RMS. *Expert Opinion on Drug Delivery*, 12(8). (DOI nicht verfügbar)
41. Kallmann, B. A., Mäurer, M., Linker, R., & Schwab, S. (2014). Bedeutung regionaler Netzwerke bei der Versorgung von MS-Patienten. *DNP – Der Neurologe und Psychiater*, 15(12). (DOI nicht verfügbar)
42. Linker, R., Kallmann, B. A., Kleinschnitz, C., Rieckmann, P., Mäurer, M., & Schwab, S. (2015). „Time is brain“ in relapsing remitting multiple sclerosis: Current treatment concepts in immunotherapy. *Der Nervenarzt*, 86, 1528–1537. <https://doi.org/10.1007/s00115-015-4350-7>
43. Metz, I., Rieckmann, P., Kallmann, B. A., & Brück, W. (2016). Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis. *Acta Neuropathologica Communications*, 4, 81. <https://doi.org/10.1186/s40478-016-0352-1>

44. Schmidt, S., Koehler, J., Winterstein, C., Schicklmaier, P., & Kallmann, B. for the EPIDEM Investigators. (2018). An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM). *Therapeutic Advances in Neurological Disorders*, 11. <https://doi.org/10.1177/1756285617749802>
45. Huhn, K., Bayas, A., Doerck, S., Frank, B., Gerbershagen, K., Hellwig, K., Kallmann, B., Kleinschnitz, C., Kleiter, I., Lee, D. H., Limmroth, V., Mäurer, M., Meuth, S. G., Rieckmann, P., Ruck, T., & Gold, R. (2018). Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: A multi-center observational study. *Journal of Neurology*. <https://doi.org/10.1007/s00415-018-8871-2>
46. Haghikia, A., Linker, R., Kallmann, B., Schlegel, E., Tackenberg, B., & Ziemssen, T. (2018). Dimethylfumarat – Therapiemanagement in der neurologischen Praxis. *Thieme Praxis Report*, 10, 1–12. (DOI nicht verfügbar)
47. Kallmann, B. A., Tiel-Wilck, K., Kullmann, J. S., Engelmann, U., & Chan, A. (2019). Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. *Therapeutic Advances in Neurological Disorders*, 12, 1–14. <https://doi.org/10.1177/1756286419844312>
48. Meuth, S. G., Bayas, A., Kallmann, B., Kleinschnitz, C., Linker, R., Rieckmann, P., & Mäurer, M. (2020). Long-term management of multiple sclerosis patients treated with cladribine tablets: An expert opinion. *Expert Opinion on Pharmacotherapy*, 1–5. <https://doi.org/10.1080/14656566.2020.1792885>
49. Wiendl, H., Gold, R., Berger, T., Derfuss, T., Linker, R., Mäurer, M., Aktas, O., Baum, K., Berghoff, M., Bittner, S., Chan, A., Czaplinski, A., Deisenhammer, F., Di Pauli, F., Du Pasquier, R., Enzinger, C., Fertl, E., Gass, A., Gehring, K., Gobbi, C., Goebels, N., Guger, M., Haghikia, A., Hartung, H. P., Heidenreich, F., Hoffmann, O., Kallmann, B., Kleinschnitz, C., Klotz, L., Leussink, V. I., Leutmezer, F., Limmroth, V., Lünemann, J. D., Lutterotti, A., Meuth, S. G., Meyding-Lamadé, U., Platten, M., Rieckmann, P., Schmidt, S., Tumani, H., Weber, F., Weber, M. S., Zettl, U. K., Ziemssen, T., & Zipp, F. (2021). Multiple Sclerosis Therapy Consensus Group (MSTCG): Position statement on disease-modifying therapies for multiple sclerosis (white paper). *Therapeutic Advances in Neurological Disorders*, 14. <https://doi.org/10.1177/17562864211039648>
50. Wiendl, H., Gold, R., Berger, T., Derfuss, T., Linker, R., Mäurer, M., Stangel, M., Aktas, O., Baum, K., Berghoff, M., Bittner, S., Chan, A., Czaplinski, A., Deisenhammer, F., Di Pauli, F., Du Pasquier, R., Enzinger, C., Fertl, E., Gass, A., Gehring, K., Gobbi, C., Goebels, N., Guger, M., Haghikia, A., Hartung, H. P., Heidenreich, F., Hoffmann, O., Hunter, Z. R., Kallmann, B., Kleinschnitz, C., Klotz, L., Leussink, V., Leutmezer, F., Limmroth, V., Lünemann, J. D., Lutterotti, A., Meuth, S. G., Meyding-Lamadé, U., Platten, M., Rieckmann, P., Schmidt, S., Tumani, H., Weber, M. S., Weber, F., Zettl, U. K., Ziemssen, T., & Zipp, F. (2021). Multiple sclerosis treatment consensus group (MSTCG): Position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper). *Nervenarzt*, 92(8), 773–801. <https://doi.org/10.1007/s00115-021-01157-2>
51. Kallmann, B. A., Ries, S., Kullmann, J. S., Quint, L. M., Engelmann, U., & Chan, A. (2021). Teriflunomide in relapsing-remitting multiple sclerosis: Outcomes by age and pre-treatment status. *Therapeutic Advances in Neurological Disorders*, 14. <https://doi.org/10.1177/17562864211005588>
52. Meuth, S. G., Bayas, A., Kallmann, B., Linker, R., Rieckmann, P., Wattjes, M., Mäurer, M., & Kleinschnitz, C. (2022). Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. *Expert Opinion on Pharmacotherapy*. <https://doi.org/10.1080/14656566.2022.2106783>
53. Kallmann, B. (2023). Biologisch ähnlich – Biosimilars in der Therapie der Multiplen Sklerose. *DNP*, 24, 40–45. <https://doi.org/10.1007/s15202-023-5667-8>

54. Krause, N., Derad, C., von Glasenapp, B., Riemann-Lorenz, K., Temmes, H., van de Loo, M., Friede, T., & Heesen, C.; POWER@MS1 Study Group. (2023). Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial. *Multiple Sclerosis and Related Disorders*. <https://doi.org/10.1016/j.msard.2023.105043>
55. Mäurer, M., Meier, U., Wattjes, M. P., Ziemssen, T., Wiendl, H., & Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). (2023). Ambulante spezialfachärztliche Versorgung (ASV) für die Multiple Sklerose. *DGNeurologie*. <https://doi.org/10.1007/s42451-023-00594-4>
56. Kallmann, B. A., Eulenburg, G., Kullmann, J., & Mäurer, M. (2024). TAURUS-MS II: Real-world use of teriflunomide in Germany and changes in treatment patterns over time. *Therapeutic Advances in Neurological Disorders*, 17, 1–17. <https://doi.org/10.1177/17562864241252>
57. Schwab, M., Chan, A., Eser, A.-K., Kallmann, B., Pöhlau, D., Richter, J., Wagner, T., & Grothe, C. (2024). REBISTART: Adherence of multiple sclerosis patients to treatment with subcutaneous interferon beta in the context of a patient support program. *Neurology and Therapy*. <https://doi.org/10.1007/s40120-024-00593-x>
58. Gross, C. C., Schulte-Mecklenbeck, A., Steinberg, O. V., Wirth, T., Lauks, S., Bittner, S., Schindler, P., Baranzini, S. E., Groppa, S., Bellmann-Strobl, J., Bünger, N., Chien, C., Dawin, E., Eveslage, M., Fleischer, V., Gonzalez-Escamilla, G., Gisevius, B., Goebels, N., Guger, M., Haghikia, A., Hartung, H. P., Heidenreich, F., Hoffmann, O., Kallmann, B. A., Lubner, G., Heider, T., Klotz, L., Chunder, R., & Kuerten, S. (2024). Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. *Science Translational Medicine*, 16(740), eade8560. <https://doi.org/10.1126/scitranslmed.ade8560>
59. Foley, J. F., Defer, G., Ryerson, L. Z., Cohen, J. A., Arnold, D. L., Butzkueven, H., Cutter, G., Giovannoni, G., Killestein, J., Wiendl, H., Smirnakis, K., Xiao, S., Kong, G., Kuhelj, R., Campbell, N.; NOVA study investigators. (2022). Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): A randomised, controlled, open-label, phase 3b trial. *Lancet Neurology*, 21(7), 608–619. [https://doi.org/10.1016/S1474-4422\(22\)00143-0](https://doi.org/10.1016/S1474-4422(22)00143-0)
60. Montalban, X., Vermersch, P., Arnold, D. L., Bar-Or, A., Cree, B. A. C., Cross, A. H., Kubala Havrdova, E., Kappos, L., Stuve, O., Wiendl, H., Wolinsky, J. S., Dahlke, F., Le Bolay, C., Shen Loo, L., Gopalakrishnan, S., Hyvert, Y., Javor, A., Guehring, H., Tenenbaum, N., Tomic, D.; evolutionRMS investigators. (2024). Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): Two multicentre, randomised, double-blind, active-controlled, phase 3 trials. *Lancet Neurology*, 23(11), 1119–1132. [https://doi.org/10.1016/S1474-4422\(24\)00328-4](https://doi.org/10.1016/S1474-4422(24)00328-4)
61. Berthele, A., Gödel, C., Kallmann, B. A., Kowarik, M., Lehmann-Horn, K., Marziniak, M., Rauer, S., Rothhammer, V., Bergh, F. T., Wahl, M., Wildemann, B., & Schirduan, K. (2025). A multicenter, prospective cohort study on the anti-SARS-CoV-2 vaccination response in patients with multiple sclerosis in Germany. *Frontiers in Neurology*, 16, 1674742. <https://doi.org/10.3389/fneur.2025.1674742>
62. Dahl, J. R., Weier, A., Winter, C., Hintze, M., Rothhammer, V., Tsaktanis, T., Proebstel, A. K., Neziraj, T., Poessnecker, E., Oechtering, J., Kuhle, J., Kallmann, B. A., Lubner, G., Heider, T., Klotz, L., Chunder, R., & Kuerten, S. (2025). Modulator of VRAC current 1 is a potential target antigen in multiple sclerosis. *Neurology: Neuroimmunology & Neuroinflammation*, 12(2), e200374. <https://doi.org/10.1212/NXI.000000000200374>
63. Krause, N., Derad, C., von Glasenapp, B., Riemann-Lorenz, K., Meyer, B., Asendorf, T., Temmes, H., van de Loo, M., Gold, S. M., Schubert, C., Stürner, K. H., Warnke, C., Schmidt, S., Friede, T., & Heesen, C.; POWER@MS1 Study Group. (2025). Digital lifestyle management application (levidex) for empowerment and health behaviour change in early multiple sclerosis – Results of the randomised controlled POWER@MS1 trial. *Multiple Sclerosis*, 31(10), 1231–1242. <https://doi.org/10.1177/13524585251356410>